email@example.com • (303) 788-5737
Swedish Family Medicine Residency Program
Swedish Medical Center
Office Hours: By appointment only
Dr. Vandiver joined the University of Wyoming School of Pharmacy in July 2012 as a Clinical Assistant Professor of Pharmacy Practice. Upon graduating from the University of Colorado Health Sciences Center with a Doctor of Pharmacy in 2010, he completed a PGY1 pharmacy practice residency at Exempla Saint Joseph Hospital, located in Denver, Colorado.
Dr. Vandiver then went on to complete a PGY2 internal medicine specialty residency, also at Exempla Saint Joseph Hospital. He is a Board Certified Pharmacotherapy Specialist. His current practice site is at Swedish Medical Center in Englewood, Colorado, practicing as an inpatient clinical pharmacist with the Swedish Family Medicine Residency Program. His academic interests include anticoagulation, pain management, cardiology, and transitions of care. Dr. Vandiver offers internal medicine rotations at Swedish Medical Center.
Pharm.D. (University of Colorado), B.A. Sociology (University of Colorado)
Anticoagulation, pain management, cardiology, infectious diseases, transitions of care
American College of Clinical Pharmacy (ACCP)
American Association of Colleges of Pharmacy (AACP)
American Society of Health-System Pharmacists (ASHP)
Anticoagulation Network Facilitator (2015-2017): Section of Clinical Specialists and Scientists
PHCY 6470—Internal Medicine Pharmaceutical Care I
PHCY 6471—Internal Medicine Pharmaceutical Care II
PHCY 6465- Inpatient Anticoagulation Elective Rotation
PHCY 6152 (OTC analgesics)
PHCY 6220 (Renal)
PHCY 6251 Therapeutics II (Renal)
PHCY 6350 Therapeutics III (Pain management)
PHCY 6357 Clinical Pharmacokinetics (Vancomycin)
PHCY 6351 Therapeutics IV (Stroke, seizure, and cardiology)
McBryde M, Vandiver JW, Onysko M. Transitions of care in medical education: A compilation of effective teaching methods. Family Medicine. 2016; 48(4): 265-272. [Corresponding author]
Vandiver JW, Singer Z, Harshberger C. Severe hyponatremia and immune nephritis following an initial infusion of nivolumab. Targeted Oncology. 2016 Mar 4. Epub ahead of print. DOI 10.1007/s11523-016-0426-9.
Vandiver JW, Ritz LI, Lalama JT. Chemical Prophylaxis to Prevent Venous Thromboembolism in Morbid Obesity: Literature Review and Dosing Recommendations. Journal of Thrombosis and Thrombolysis. 2016; 41(3): 475-481.
Lalama JT, Feeney ME, Vandiver JW, Beavers KD, Walter LN, McClintic JR. Assessing an enoxaparin dosing protocol in morbidly obese patients. Journal of Thrombosis and Thrombolysis. 2015; 39(4): 516-521.
Mlodinow SG, Onysko MK, Vandiver JW, Hunter ML, Mahvan TD. Statin adverse effects: Sorting out the evidence. Journal of Family Practice. 2014; 63(9): 497-506.
Lalama JT, Feeney ME, Vandiver JW, Beavers KD, Walter LN, McClintic JR. Assessing an enoxaparin dosing protocol in morbidly obese patients. Journal of Thrombosis and Thrombolysis. 2014 Aug 3. [Epub ahead of print].
Vandiver JW, Faulkner D, Erlandson M, Onysko M. Novel oral anticoagulants: Appropriate patient selection. Journal of Family Practice. 2014 Jan;63(1):22-8.
Vandiver JW, Vondracek TG. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring. Hospital Practice. 2013 Apr; 41(2): 16-24.
Vandiver JW, Vondracek TG. Antifactor Xa Levels versus Activated Partial Thromboplastin Time for Monitoring Unfractionated Heparin. Pharmacotherapy. 2012 Jun;32(6):546-58.